Cholecalciferol (Vitamin D3) and the retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) are synergistic for chemoprevention of prostate cancer

Journal of Experimental Therapeutics and Oncology

Volumn 5, Issue 4, 2006, Pages 323-333

  Tokar, Erik J ^a,b   Ancrile, Brooke B ^a   Ablin, Richard J ^c   Webber, Mukta M ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

4 HPR; Chemoprevention; Cholecalciferol; Human cell lines; Prostate; Receptors; Retinoid; Synergism; Vitamin D

Indexed keywords

ALCOHOL; C 1357; COLECALCIFEROL; FENRETINIDE; GELATINASE A; RECEPTOR SUBTYPE; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR; RETINOID X RECEPTOR ALPHA; RETINOID X RECEPTOR BETA; RETINOID X RECEPTOR GAMMA; VIMENTIN; VITAMIN D RECEPTOR; ANTINEOPLASTIC AGENT; RETINOID; VITAMIN;

ARTICLE; CANCER CHEMOTHERAPY; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG POTENTIATION; ENZYME ACTIVITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; WESTERN BLOTTING; GENE EXPRESSION REGULATION; MALE; METABOLISM; PROSTATE TUMOR; UPREGULATION;

ANTICARCINOGENIC AGENTS; CHOLECALCIFEROL; DRUG SYNERGISM; FENRETINIDE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; PROSTATIC NEOPLASMS; RETINOIDS; UP-REGULATION; VIMENTIN; VITAMINS;

EID: 33749362734     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. American Cancer Society: Cancer Facts and Figures 2005, Atlanta, GA, 52 pp., 2005.
2. Sakr WA, Haas GP, Cassin BF, Pontes JE, and Crissman DG. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 150:379-385, 1993.
3. Sakr WA, Billis A, Ekman P, Wilt T, and Bostwick DG. Epidemiology of high-grade prostatic intraepithelial neoplasia. Scand J Urol Nephrol 205 (Suppl.):11-18, 2000.
4. Webber, MM, Bello-DeOcampo, D, Quader S, Deocampo ND, Metcalfe WS, and Sharp RM. Modulation of the malignant phenotype of human prostate cancer cells by N-(4-hydroxyphenyl)retinamide (4-HPR). Clin Exp Metastasis 17:255-263, 1999.
5. O'Shaughnessy, JA., Kellof GJ, Gordon GB, Dannenberg AJ, Hong WK, Fabian CJ, Sigman CC, Bertagnolli MM, Stratton SP, Lam S, Nelson WG, Meyskens FL, Alberts DS, Follen M, Rustgi AK, Papadimtrakopoulou V, Scardino PT, Gazdar AF, Wattenberg LW, Soprn MB, Sakr WA, Lippman SM, and Von Hoff DD. Treatment and prevention of intraepithelial neoplasia: An important target for accelerated new agent development. Recommendations of the American Association for Cancer Research task force on the treatment and prevention of intraepithelial neoplasia. Clin Cancer Res 8:314-316, 2002.
6. Sporn MB, and Suh N. Chemoprevention: An essential approach to controlling cancer. Nature Reviews, Cancer 2:537-543, 2002.
7. Hong WK, and Sporn MB. Recent advances in Chemoprevention of cancer. Science 278:1073-1077, 1997.
8. Greenwald P. Prospects for Chemoprevention. In: Chemoprevention of Cancer, DW Nixon (ed.), Boca Raton, FL, CRC Press, pp. 1-8, 1995.
9. Sharp RM, Bello-DeOcampo D, Quader S, and Webber MM, N-(4-hydroxyphenyl) retinamide (4-HPR) decreases neoplastic properties of human prostate cells: an agent for prevention. Mut Res 496:163-170, 2001.
10. Sporn MB, Dunlop NM, Newton DL, and Smith JM. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 35:1332-1338, 1976.
11. 3): 25-hydroxylase (CYP27A1) in human prostate epithelial cells. Clin Exp Metastasis 22:265-273, 2005.
12. 3) inhibits growth and invasion by up-regulating nuclear receptors and 25-hydroxylase (CYP27A1) in human prostate cancer cells. Clin Exp Metastasis 22:275-284, 2005.
13. Garland CF, Garland FC and Gorham ED. Epidemiology of cancer risk and vitamin D. In: Vitamin D: Physiology, Molecular Biology, and Clinical Applications, MF Holick (ed.), Totowa, NJ, Humana Press, pp. 307-316, 1999.
14. Reichman ME, Hayes RB, Ziegler RG, Schatzkin A, Taylor PR, and Fraumeni JF. Serum vitamin A and subsequent development of prostate cancer in the first National Health an Nutrition Examination Survey Epidemiologic Follow-up Study. Cancer Res 50:2311-2315, 1990.
15. Quader S, Bello-DeOcampo D, Williams DE, Kleinman HK, and Webber MM. Evaluation of the chemopreventive potential of retinoids using a novel in vitro human prostate carcinogenesis model. Mut Res 496:153-161, 2001.
16. Waghray A, and Webber MM. Retinoic acid modulates extracellular urokinase-type plasminogen activator activity in DU-145 human prostatic carcinoma cells. Clin Cancer Res 747-753, 1995.
17. Webber MM, and Waghray A. Urokinase-mediated extracellular matrix degradation by human prostatic carcinoma cells and its inhibition by retinoic acid. Clin Cancer Res 1:755-761, 1995.
18. 3. Cancer Epidemiol Biomarkers & Prev 7:391-395, 1998.
19. 1. Endocrinology 138: 1491-1497, 1997.
20. 3 analog. Endocrinology 139:1972-1979, 1998.
21. 3 analog combined with 9-cis-retinoic acid markedly inhibits colony growth of prostate cancer cells. Prostate 40:141-149, 1999.
22. Rivette AS, Tokar EJ, Williams DE, MacKenzie CD, Ablin, RJ, and Webber MM. Selection of cell lines with enhanced invasive phenotype from xenografts of the human prostate cancer cell line WPE1-NB26. J Exp Therap Oncol 5:111-123, 2005.
23. Bello D, Webber MM, Kleinman HK, Wartinger DD, and Rhim JS. Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis 18:1215-1223, 1997.
24. Webber MM, Bello-DeOcampo D, Kleinman HK, and Hoffman MP. Acinar differentiation by non-malignant immortalized human prostatic epithelial cells and its loss by malignant cells. Carcinogenesis 18:1225-1231, 1997.
25. Webber MM, Quader S, Kleinman HK, Bello-DeOcampo D, Storto P, Bice G, DeMendonca-Calaca W, and Williams DE. Human cell lines as an in vitro/in vivo model for prostate carcinogenesis and progression. Prostate 47:1-13, 2001.
26. Stearns ME and Stearns M. Evidence for increased activated metalloproteinase-2(MMP-2a) expression associated with human prostate cancer progression. Oncol Res 8:69-75, 1996.
27. Lang SH, Hyde C, Reid IN, Hitchcock IS, Hart CA, Bryden AA, Villette J-M, Stower MJ, and Maitland NJ. Enhanced expression of vimentin in motile prostate cell lines in poorly differentiated and metastatic prostate carcinoma. Prostate 52: 253-263, 2002.
28. Coussens LM, Fingleton B., and Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trial and tribulations. Science 295:2387-2392, 2002.
29. Montironi R, Lucarini G, Castaldini C, Galluzzi CM, Biagini G, and Fabris G. Immunohistochemical evaluation of type IV collagenase (72-kDa metalloproteinase) in prostatic intraepithelial neoplasia. Anticancer Res 16:2057-2062, 1996.
30. Glass CK. Differential recognition of target genes by nuclear receptor monomers, dimers, and heterodimers. Endocrine Rev 15:391-407, 1994.
31. Schrader M, Bendik I, Becker-Andre M, Carlberg C. Interaction between retinoic acid and vitamin D signaling pathway. J Biol Chem 268:17830-17836, 1993.
32. Huang J, Powell WC, Khodavirdi AC, Wu J, Makita T, Cardiff RD, Cohen MB, Sucov HM, and Roy-Burnam P. Prostatic intraepithelial neoplasia in mice with conditional disruption of the retinoid X receptor α allele in the prostate epithelium. Cancer Res 62:4812-4819, 2002.
33. Kephart DD, Walfish PG, DeLuca H and Butt TR. Retinoid X receptor isotype identity directs human vitamin D receptor heterodimer transactivation from the 24-hydroxylase vitamin D response element in yeast. Mol Endocrinol 10:408-419, 1996.
34. Hatoum A, El-Sabban ME, Khoury J, Yuspa SH, and Darwiche N. Overexpression of retinoic acid receptors alpha and gamma into neoplastic epidermal cells causes retinoic acid-induced growth arrest and apoptosis. Carcinogenesis 22:1955-1963, 2001.
35. waf1/cip1 gene by retinoic acid receptor. J Biol Chem 271:31723-31728, 1996.
36. 3 in NRP-152 rat prostatic epithelial cells. J Cell Physiol 166:231-239, 1996.